Issues
-
Cover Image
Cover Image
B-RafV600E inhibitors are potent at halting melanoma progression in patients harboring oncogenic B-RafV600E mutation. Recent studies indicate that chemotherapies and other target treatments suppress tumor growth via a host immunity-dependent manner. Using a genetically modified mouse model of melanoma, it was found that diminished CD40L- and IFNγ-mediated signaling contributed to the formation of immunosuppressive tumor microenvironment and that treatment with a BrafV600E inhibitor, PLX4720, could reinvigorate local immune function. Indeed, maximal effectiveness of PLX4720 was dependent on restoration of CD40L- and IFNγ-mediated immune signals. This study illustrates that certain chemotherapies directed at the tumor rely on immune signaling pathways and that this has relevance for the design of combined treatments with immunotherapies. For details, see the article by Ho and colleagues on page 3205. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Review
Microenvironment and Immunology
Molecular and Cellular Pathobiology
Global Transcriptome Analysis of Formalin-Fixed Prostate Cancer Specimens Identifies Biomarkers of Disease Recurrence
Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
Prevention and Epidemiology
Noninvasive Urinary Metabolomic Profiling Identifies Diagnostic and Prognostic Markers in Lung Cancer
Therapeutics, Targets, and Chemical Biology
Notch3 Pathway Alterations in Ovarian Cancer
Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling
IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism
Tumor and Stem Cell Biology
Transient Induction of ING4 by Myc Drives Prostate Epithelial Cell Differentiation and Its Disruption Drives Prostate Tumorigenesis
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.